Bystolic (nebivolol) is a small molecule pharmaceutical. Nebivolol was first approved as Bystolic on 2007-12-17. It is used to treat malignant hypertension in the USA. It is known to target beta-3 adrenergic receptor, beta-2 adrenergic receptor, and beta-1 adrenergic receptor. Bystolic's patent is valid until 2021-12-17 (FDA).
|Drug Class||Beta-blockers (propranolol type)|